Citations

Clear

3942 citation(s) found for "To, Van".

Digital Regenerative Medicine and Surgery Pedagogy for Virtual Learning in the Time of COVID-19
Wyles, Saranya P. , Meyer, Fredric B. , Hayden, Richard E. , Scarisbrick, Isobel A. , Terzic, André , Hayden, Richard , Scarisbrick, Isobel A , Terzic, Andre

Mayo Clinic

Regenerative Medicine | August 26, 2020 | Volume: 15 | Issue: 8 | Pages: 1937-1941

10.2217/rme-2020-0106 | PMID 32844717 Get It

Cytogenetic abnormalities in mesenchymal stem cells in chronic lymphocytic leukemia (CLL) patients and normal subjects
Knox, Traci R., Smoley, Stephanie A., Dyke, Daniel L. Van , Ding, Wei , Kay, Neil E.

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: e22002-e22002

10.1200/jco.2009.27.15_suppl.e22002 Get It

e22002 Background: Mesenchymal stem cells (MSC) residing in the marrow support hematopoiesis and protect cancer cells from undergoing cell death induced by chemotherapy. Recent reports have described clonal cytogenetic abnormalities in the MSC of acute myeloid leukemia and myelodysplastic syndrome patients. To determine if cytogenetic abnormalities are present in MSC from CLL patients, we analyzed karyotypes of MSC from 13 CLL patients and 5 normal subjects. Methods: Stromal cells from marrow core biopsies of 13 CLL patients and 5 normal control subjects were isolated, cultured and confirmed as MSC based on their immunophenotype and capacity to differentiate into three lineages. After 3–4 non-stimulated cell culture passages, the karyotype was analyzed in 5–40 metaphase cells from each subject Abnormalities were considered clonal using the accepted convention of the same chromosomal gain or rearrangement in 2 or more cells or loss in at least 3 cells. For each CLL patient, interphase FISH analysis to detect the common CLL-associated abnormalities was performed on freshly isolated peripheral blood mononuclear cells (PBMC). Results: Clonal cytogenetic abnormalities of the cultured MSC were observed in 6 of 13 CLL patients (46%) and 3 of 5 control subjects (60%). The 6 CLL MSC had different clonal abnormalities than the PBMC CLL FISH studies. One CLL MSC exhibited trisomy 5, one exhibited trisomy 8, and one had monosomy X clone. One MSC had a balanced t(1;16). One MSC had a balanced t(3;12) and a del(3p), and one had a complex karyotype with 4 unbalanced rearrangements. The clonal aberrations observed in the 3 controls included a del(3p) in two cases, and in one case an inv(5) and a del(10q). There was no correlation of the chromosomal abnormalities in CLL MSC with clinical stage. Conclusions: Marrow MSC derived from CLL patients and normal subjects do show an array of cytogenetic abnormalities including clonal chromosomal abnormalities. However the genetic abnormalities found in both CLL and normal MSC could represent acquired genomic instability associated with advanced age, rather than oncogenesis associated with CLL. [Table: see text]
A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214
Gore, E., Bae, K., Wong, Stephanie M. , Bonner, J., Gaspar, Laurie E., Bogart, J.J. Van, Werner‐Wasik, Maria, Choy, H. , Wong, S., Sun, A. , Schild, Steven E. , Bogart, J.

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 7506-7506

10.1200/jco.2009.27.15_suppl.7506 Get It

7506 Background: The incidence of central nervous system (CNS) metastases is high in patients with locally advanced non-small cell lung cancer. Brain as an only site of relapse appears increasingly common as loco-regional and extra-cranial systemic treatment improves. There is not standard agreement as to how to address this risk. Methods: Patients with stage III NSCLC without progression of disease after loco-regional treatment with surgery and/or radiation therapy with or without chemotherapy were eligible. Participants were randomized to prophylactic cranial irradiation (PCI) or observation and stratified by stage (IIIA or B), histology (non-squamous or squamous) and therapy (surgery or no surgery). PCI was delivered once daily at 2Gy per fraction to 30Gy. The primary endpoint of the study was overall survival (OS). Secondary endpoints were disease free survival (DFS) and the impact of PCI on incidence of CNS metastases, neuropsychological function, and quality of life (QoL). Kaplan- Meier estimation with the log-rank test was used for OS and DFS and the logistic regression model was used for calculating the incidence of CNS metastasis. Results: Total accrual was 356 patients of the targeted 1058 between 9/19/02 and 8/30/07. The study was closed early due to slow accrual. 340 patients were evaluable. One year OS (p=0.86, 75.6 % and 76.9% for PCI and observation) and one year DFS (p=0.11, 56.4% and 51.2% for PCI and observation) were not statistically significantly different. However, CNS metastatic rate at 1 year was statistically significantly different with CNS relapse 7.7% vs. 18% for PCI vs. observation (p=0.004). Logistic regression showed that the patients in the observation arm are 2.52 times more likely to develop CNS metastases than those in the PCI arm (odds ratio=2.52, 95% CI=(1.32–4.80)). Conclusions: PCI in patients without progressive disease after loco-regional therapy for III NSCLC significantly decreases the rate of CNS metastases. This study did not show a statistically significant difference in OS or DFS. Forthcoming analysis of the impact of PCI on neuropsychological function and QoL will influence the recommendations regarding the standard use of PCI. No significant financial relationships to disclose.
Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, a
Cassidy, Jim , Gramont, Armand de, Group, The Adjuvant Colon Cancer Endpoints (ACCENT), Sargent, Daniel J. , Yothers, Greg , Cutsem, Eric Van , Saltz, Leonard B. , Wolmark, Norman , Shi, Qiuling , Buyse, Marc , Group, The Adjuvant Colon Cancer Endpoints (ACCENT)

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 4011-4011

10.1200/jco.2009.27.15_suppl.4011 Get It

4011 Background: The ACCENT group previously validated DFS with 3 years (yr) median follow-up (f-up) based on 20,898 pts from trials testing 5-FU based regimens (rx) (3yr DFS) as an endpoint to predict overall survival with 5 yr median f-up (5yr OS) (Sargent, JCO 2005). ACCENT further proposed (1) 2yr DFS predicts 5yr OS, (2) a stronger relationship between DFS and OS in stage III pts (Sargent JCO 2007) and (3) 6 or 7 yrs are necessary to demonstrate DFS and OS association in future trials due to extended survival following recurrence (de Gramont ASCO 2008). The relationship between endpoints in more recent trials with oral fluoropyrimidines, oxaliplatin, and irinotecan is unknown. Methods: Concordance between 2 and 3yr DFS, and 5 and 6yr OS was examined in 6 randomized phase III trials from 1997–2002. Individual data for 12,676 pts was analyzed; 2 trials tested oxaliplatin, 2 irinotecan, and 2 oral rx vs 5-FU/LV control. Association between DFS and OS hazard ratios (HRs) via weighted least squares (WLS), and concordance between predicted and actual within-trial HRs, were calculated overall and for stage III pts. Results: Overall association between 3 yr DFS and 5 yr OS HRs was reduced compared to the prior ACCENT analysis (Table). In stage III pts, the association between DFS and OS HRs remained strong. Observed 5 and 6yr OS HRs were predicted accurately by 2yr DFS overall and in stage III pts (within 95% prediction limits in all trials). In all pts, DFS HRs were more highly associated with 6 vs 5yr OS HRs. Conclusions: In recent trials in stage III pts, DFS HRs based on 2yr median f-up are highly predictive of 5 and 6yr OS HRs. In all pts the association between DFS and OS HRs is stronger for 6yr OS, but 7yr follow-up may be required. These data support 3yr DFS as a primary endpoint for modern stage III trials, and indicate that 2yr DFS would also be an appropriate primary endpoint. [Table: see text] [Table: see text]
Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database
McCleary, N. A. Jackson, Green, E., Gramont, Armand de, O'Connell, M J, Twelves, Chris , Group, The ACCENT Collaborative, Meyerhardt, Jeffrey A. , Green, E. M., Yothers, Greg , Cutsem, Eric Van , Saltz, Leonard B. , Sargent, Daniel J. , Group, The ACCENT Collaborative

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 4010-4010

10.1200/jco.2009.27.15_suppl.4010 Get It

4010 Background: Prior studies suggested that older and younger pts with colon cancer receive similar benefit from IV fluoropyrimidine (FU) adjuvant (adj) therapy (rx). Combination and/or oral FU rx are increasingly given as adj rx. We sought to determine the impact of pts age <70 v ≥70 yrs on colon cancer recurrence and mortality from adj rx with these newer options. Methods: We used data from 10,499 pts <70 yrs and 2,170 pts ≥70 yrs in 6 phase III adj rx trials comparing IV FU to combinations with irinotecan, oxaliplatin or oral FU (capecitabine and UFT/LV) in stage II/III colon cancer from the ACCENT database. Endpoints were overall survival (OS; time to death), disease-free survival (DFS; time to recurrence or death), and time to recurrence (TTR; censoring at last follow-up). Cox models were stratified by age and adjusted for gender and stage; interaction testing was used to explore the differential benefit by age. Results: Approximately 75% of pts had stage III disease (74% age<70, 77% age≥70). OS, DFS, and TTR were statistically significantly improved for those in the experimental v control arms among pts <70 but not those >70 ( table ); the interaction between age and rx was statistically significant for all endpoints (p=0.01 for OS, DFS, and TTR). These results were consistent whether experimental rx was oxaliplatin-based, irinotecan-based or oral FU. Deaths in first 6 month of adj rx were not statistically significantly different between experimental and control arm. Conclusions: Our results show conclusively that pts >70 do not receive the same benefit from combination and/or oral FU as those <70. Any benefit, if present, compared to IV FU/LV would not be clinically meaningful. Outcomes of experimental (combination or oral FU) vs control (IV 5-FU) by treatment and age [Table: see text] [Table: see text]
Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study
James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Sylte, Dillon O , Bertolacci, Gregory J, Cunningham, Matthew , LeGrand, Kate E , Abdelalim, Ahmed , Abdulkader, Rizwan Suliankatchi , Abedi, Aidin , Abegaz, Kedir Hussein , Eshete, Akine , Abushouk, Abdelrahman Ibrahim , Adebayo, Oladimeji , Advani, Shailesh M, Agudelo‐Botero, Marcela , Ahmad, Tauseef , Aichour, Miloud Taki Eddine, Alahdab, Fares , Alanezi, Fahad , Alema, Niguse Meles , Wassihun, Biresaw , Ali, Beriwan Abdulqadir, Alipour, Vahid, Almasri, Nihad A. , Altirkawi, Khalid A , Amer, Yasser Sami , Andrei, Cătălina Liliana , Ansari-Moghaddam, Alireza, Antonio, Carl Abelardo T, Anvari, Davood , Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Ariani, Filippo , Arora, Amit , Quintanilla, Beatriz Paulina Ayala , Ayano, Getinet , Ayanore, Martin Amogre , Azarian, Ghasem , Badawi, Alaa, Badiye, Ashish , Baig, Atif Amin , Bairwa, Mohan , Bakhtiari, Ahad , Banerjee, Srikanta , Banik, Palash Chandra , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Barzegar, Akbar , Belete, Habte , Bennett, Derrick , Berhe, Kidanemaryam , Bhagavathula, Akshaya Srikanth , Bhardwaj, Pankaj , Bhat, Anusha Ganapati , Bhattacharyya, Krittika , Bhutta, Zulfiqar A , Bibi, Sadia , Bijani, Ali , Borschmann, Rohan , Borzì, Antonio Maria , Braithwaite, Dejana , Брико, Н. И. , Brugha, Traolach , Budhathoki, Shyam Sundar , Car, Josip , Cárdenas, Rosario , Carvalho, Félix , Castaldelli-Maia, João Maurício , Castañeda-Orjuela, Carlos A , Castelpietra, Giulio , Catalá-López, Ferrán , Cerin, Ester , Chandan, Joht Singh , Chapman, Jens R. , Chattu, Vijay Kumar , Chattu, Soosanna Kumary , Chaudhary, Neha , Cho, Daniel , Choi, Jee-Young J, Chowdhury, Mohiuddin Ahsanul Kabir , Christopher, Devasahayam Jesudas , Chu, Dinh‐Toi , Costa, Vera Marisa , Dávila-Cervantes, Claudio Alberto , Leo, Diego De, Demoz, Gebre Teklemariam , Demsie, Desalegn Getnet , Deribe, Kebede , Desai, Rupak , Nasab, Mostafa Dianati, Silva, Diana Dias da , Forooshani, Zahra Sadat Dibaji, Doyle, Kerrie , Driscoll, Tim , Dubljanin, Eleonora , Adema, Bereket Duko , Eagan, Arielle Wilder , Elemineh, Demelash Abewa , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Eyawo, Oghenowede , Faris, Pawan , Faro, André , Farzadfar, Farshad , Fereshtehnejad, Seyed-Mohammad , Fernandes, Eduarda , Ferrara, Pietro , Fischer, Florian , Foláyan, Morẹ́nikẹ́ Oluwátóyìn , Fomenkov, Artem Alekseevich , Francis, Joel M , Fukumoto, Takeshi , Geberemariyam, Biniyam Sahiledengle, Gebremariam, Hadush, Gebremedhin, Ketema Bizuwork , Gebremeskel, Leake , Gebremeskel, Gebreamlak Gebremedhn , Gebremichael, Berhe , Geta, Birhanu, Ghafourifard, Mansour , Ghamari, Farhad , Gheshlagh, Reza Ghanei , Gholamian, Asadollah , Gilani, Syed Amir , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Guo, Yuming , Haagsma, Juanita A. , Hall, Brian J. , Hamadeh, Randah R , Hassan, Shoaib, Hassen, Hamid Yimam , Havmoeller, Rasmus, Heydarpour, Fatemeh , Hı́jar, Martha , Ho, Hung Chak , Hoang, Chi Linh , Hole, Michael K., Hossain, Naznin , Hosseinzadeh, Mehdi , Hostiuc, Sorin , Ibitoye, Segun Emmanuel , Inbaraj, Leeberk Raja , Irvani, Seyed Sina Naghibi , Islam, M. Mofizul , Islam, Sheikh Mohammed Shariful , Ivers, Rebecca , Jahani, Mohammad Ali, Jakovljević, Mihajlo , Jayaraman, Sudha , Jha, Ravi Prakash , John-Akinola, Yetunde O. , Joseph, Nitin , Joukar, Farahnaz, Jürisson, Mikk , Kahsay, Amaha , Kalankesh, Leila R , Kalhor, Rohollah , Kamil, Teshome Abegaz, Kapoor, Neeti , Karami, Manoochehr , Kasaeian, Amir , Kassaye, Hagazi Gebremedhin, Kavetskyy, Taras , Kayode, Gbenga A , Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khalil, Ibrahim A, Khalilov, Rovshan , Khan, Maseer , Khan, Ejaz Ahmad , Khan, Junaid , Khanna, Tripti, Khundkar, Roba , Kiirithio, Daniel N, Kim, Yun Jin , Kısa, Sezer , Kısa, Adnan , Komaki, Hamidreza , Kondlahalli, Shivakumar K M, Koolivand, Ali , Korshunov, Vladimir Andreevich , Kraemer, Moritz U. G. , Krishan, Kewal , Defo, Barthélémy Kuate , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Manasi , Kumar, Vivek , Kumar, Narinder , Kumaresh, Girikumar, Lami, Faris , Lasrado, Savita , Leasher, Janet L , Li, Shanshan , Liu, Xuefeng , Lyons, Ronan A , Machado, Daiane Borges , Madadin, Mohammed , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Majeed, Azeem , Maled, Venkatesh , Manafi, Navid , Manafi, Amir , Manda, Ana-Laura, Mansour-Ghanaei, Fariborz, Mason‐Jones, Amanda J. , Masoumi, Seyedeh Zahra , Massenburg, Benjamin B. , Maulik, Pallab K , Mehndiratta, Man Mohan, Melketsedik, Zeleke Aschalew , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Merie, Hayimro Edemealem , Miazgowski, Bartosz , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Mithra, Prasanna , Moghadaszadeh, Masoud, Mohammad, Yousef , Mohammadian-Hafshejani, Abdollah , Mohammed, Shafiu , Mohammed, Jemal , Bandpei, Mohammad Ali Mohseni, Molokhia, Mariam , Monasta, Lorenzo , Moodley, Yoshan , Moradi, Masoud , Moradi, Ghobad , Morawska, Lídia , Velásquez, Ilais Moreno , Mossie, Tilahun Belete , Musa, Kamarul Imran , Mustafa, Ghulam , Naderi, Mehdi , Nagarajan, Ahamarshan Jayaraman , Naik, Gurudatta , Naimzada, Mukhammad David , Nangia, Vinay, Nascimento, Bruno Ramos , Naserbakht, Morteza , Ndwandwe, Duduzile , Negoi, Ionuţ , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nguyen, Diep Ngoc , Nikbakhsh, Rajan , Ningrum, Dina Nur Anggraini , Nnaji, Chukwudi A , Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Oghenetega, Onome Bright , Olagunju, Andrew T , Olagunju, Tinuke O , Bali, Ahmed Omar , Onwujekwe, Obinna , Orpana, Heather , Otstavnov, Nikita , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakshir, Keyvan , Panda‐Jonas, Songhomitra, Park, Eun‐Kee , Patel, Sangram Kishor , Pathak, Ashish , Pati, Sanghamitra , Paulos, Kebreab , Pepito, Veincent Christian Filipino , Полибин, Р. В. , Polinder, Suzanne, Pourmalek, Farshad , Pourshams, Akram , Poustchi, Hossein, Prakash, Swayam , Pribadi, Dimas Ria Angga , Puri, Parul , Syed, Zahiruddin Quazi, Rabiee, Navid , Radfar, Amir , Rafay, Anwar, Rafiee, Ata , Rafiei, Alireza , Rahim, Fakher , Rahman, Muhammad Aziz , Rajabpour-Sanati, Ali, Rajati, Fatemeh , Rakovac, Ivo , Rao, Sowmya J, Rashedi, Vahid , Rawal, Lal , Rawassizadeh, Reza , Renjith, Vishnu , Resnikoff, Serge , Rezapour, Aziz, Rickard, Jennifer , Saddik, Basema , Safdarian, Mahdi , Sajadi, S. Mohammad , Salamati, Payman, Salem, Marwa Rashad , Salem, Hosni , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Schwebel, David C. , Seedat, Soraya , Senthilkumaran, Subramanian , Seyedmousavi, Seyedmojtaba , Sha, Feng , Shaahmadi, Faramarz , Shaikh, Masood Ali , Shams-Beyranvand, Mehran , Shigematsu, Mika, Shin, Jae Il , Shiri, Rahman , Sigfúsdóttir, Inga Dóra, Singh, Pankaj Kumar , Sinha, Dhirendra Narain , Soriano, Joan B. , Soyiri, Ireneous N , Sufiyan, Mu’awiyyah Babale , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Wogayehu, Biruk , Tefera, Yibekal Manaye , Tekulu, Gebretsadkan Hintsa , Kassie, Ayenew , Титова, М. В. , Tlaye, Kenean Getaneh , Tohidinik, Hamid Reza , Topór-Mądry, Roman , Tripathy, Jaya Prasad , Tsai, Alexander C. , Tsatsakis, Aristidis , Car, Lorainne Tudor , Ullah, Irfan , Ullah, Saif , Upadhyay, Era , Valdéz, Pascual , Violante, Francesco Saverio , Waheed, Yasir , Wang, Yuan‐Pang , Wiangkham, Taweewat , Wolde, Haileab Fekadu , Woldeyes, Dawit Habte , Wu, Ai-Min, Wyper, Grant M. A. , Yadav, Rajaram , Yadollahpour, Ali , Yano, Yuichiro , Yaya, Sanni , Yazdi‐Feyzabadi, Vahid , Ye, Pengpeng , Yisma, Engida , Yoon, Seok‐Jun , Youm, Yoosik , Younis, Mustafa Z , Yousefi, Zabihollah , Yu, Yong , Moghadam, Telma Zahirian , Zaman, Sojib Bin , Zarei, Fatemeh , Zhang, Zhi-Jiang, Zhang, Yunquan , Zodpey, Sanjay , Dandona, Rakhi , Dharmaratne, Samath Dhamminda , Hay, Simon I , Mokdad, Ali H. , Reiner, Robert C. , Vos, Theo , Topór‐Mądry, Roman , Feyissa, Garumma Tolu , Haghparast‐Bidgoli, Hassan , Kumar, G Anil , Zahiruddin, Quazi Syed , Dianatinasab, Mostafa , Sanati, Ali Rajabpour , Baig, Atif Amin , Kumar, Vivek , Castaldelli-Maia, João M , Farzadfar, Farshad , Shin, Jae I L , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Bhagavathula, Akshaya Srikanth , Belete, T , Liu, Zichen , Roberts, Nicholas L S , Henry, Nathaniel J , Abdollahpour, Ibrahim , Adsuar, José Carmelo , Ahmed, Muktar Beshir , Ahmed, Rushdiá , Alghnam, Suliman Abdullah , Ali, Saqib , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Antonio, Carl Abelardo T. , Arab-Zozani, Morteza , Asaad, Malke , Balachandran, Arun , Banach, Maciej , Bayati, Mohsen , Bazargan‐Hejazi, Shahrzad , Bedi, Neeraj , Behzadifar, Masoud , Benseñor, Isabela M. , Boloor, Archith , Borges, Guilherme , Boufous, Soufiane , Chatziralli, Irini , Cicuttini, Flavia , Coelho, João M, Dahlawi, Saad M A , Daryani, Ahmad , Demeke, Feleke Mekonnen , Forooshani, Zahra Sadat Dibaji, Do, Hoa , Duko, Bereket , El-Jaafary, Shaimaa I , Zaki, Maysaa El Sayed , Eskandarieh, Sharareh , Foroutan, Masoud , Franklin, Richard C. , Gebremariam, Hadush, Gedefaw, Getnet , Bante, Agegnehu , Gill, Tiffany K. , Goudarzian, Amir Hossein , Grivna, Michal , Guimarães, Rafael Alves , Gupta, Gaurav Kumar , Hamidi, Samer , Handiso, Demelash Woldeyohannes , Haro, Josep María , Hasanzadeh, Amir , Hassanipour, Soheil , Hassankhani, Hadi , Hendrie, Delia V. , Holla, Ramesh , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jalilian, Farzad , Jayatilleke, Achala Upendra , Jonas, Jost B , Jones, Kelly , Jozwiak, Jacek Jerzy , Jungari, Suresh Banayya , Kabir, Ali , Kanchan, Tanuj , Khalil, Ibrahim A, Khazaei, Salman , Khazaie, Habibolah , Kim, Young‐Eun , Kim, Daniel , Shivakumar, KM , Koyanagi, Ai , Kumar, Nithin , Lansingh, Van Charles , Latifi, Arman , Lauriola, Paolo , Vecchia, Carlo La , Lee, Shaun Wen Huey , Lopez, Alan D , Lotufo, Paulo A. , Malta, Déborah Carvalho , Manjunatha, Narayana , Mansour‐Ghanaei, Fariborz , Mansournia, Mohammad Alì , Maravilla, Joemer Calderon , Aschalew, Zeleke , Meštrović, Tomislav , Mirică, Andreea , Mirzaei-Alavijeh, Mehdi, Moazen, Babak , Mohamadi, Efat , Darwesh, Aso Mohammad , Mohammadpourhodki, Reza , Mohebi, Farnam , Moradi‐Lakeh, Maziar , Moradzadeh, Rahmatollah , Morrison, Shane D. , Muluneh, Atalay Goshu , Najafi, Farid , Nayak, Vinod C , Nazari, Javad , Nguyen, Trang Huyen , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Ota, Erika , Peden, Amy E. , Pereira, Jeevan , Phillips, Michael , Rabiee, Mohammad , Rahimi, Siavash , Rastogi, Prateek , Rathi, Priya , Rawaf, Salman , Ribeiro, Ana Isabel , Ríos-González, Carlos Miguel , Roever, Leonardo , Ronfani, Luca , Roshandel, Gholamreza , Safarpour, Hamid , Salamati, Payman, Santric-Milicevic, Milena M , Sarker, Abdur Razzaque , Sayyah, Mehdi , Shahabi, Saeed , Sheikh, Aziz , Siabani, Soraya , Singh, Ambrish , Soheili, Amin , Sorrie, Muluken Bekele , Stokes, Mark Andrew , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Thapar, Rekha , Tran, Khanh Bao , Tran, Bach Xuan , Unnikrishnan, Bhaskaran , Uthman, Olalekan Abdulrahman , Vasankari, Tommi Juhani , Veisani, Yousef , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Wondmeneh, Temesgen Gebeyehu , Wondmieneh, Adam Belay , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zandian, Hamed , Zhang, Zhi‐Jiang , Ziapour, Arash , Pigott, David M. , Olagunju, Andrew T , Baig, Atif Amin , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

Injury Prevention | August 24, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i125-i153

10.1136/injuryprev-2019-043531 | PMID 32839249 Get It

Background While there is a long history of measuring death and disability from injuries, modern research methods must account for the wide spectrum of disability that can occur in an injury, and must provide estimates with sufficient demographic, geographical and temporal detail to be useful for policy makers. The Global Burden of Disease (GBD) 2017 study used methods to provide highly detailed estimates of global injury burden that meet these criteria. Methods In this study, we report and discuss the methods used in GBD 2017 for injury morbidity and mortality burden estimation. In summary, these methods included estimating cause-specific mortality for every cause of injury, and then estimating incidence for every cause of injury. Non-fatal disability for each cause is then calculated based on the probabilities of suffering from different types of bodily injury experienced. Results GBD 2017 produced morbidity and mortality estimates for 38 causes of injury. Estimates were produced in terms of incidence, prevalence, years lived with disability, cause-specific mortality, years of life lost and disability-adjusted life-years for a 28-year period for 22 age groups, 195 countries and both sexes. Conclusions GBD 2017 demonstrated a complex and sophisticated series of analytical steps using the largest known database of morbidity and mortality data on injuries. GBD 2017 results should be used to help inform injury prevention policy making and resource allocation. We also identify important avenues for improving injury burden estimation in the future.
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
Gupta, Gagan K., Collier, Amber L. , Lee, Dasom, Zheleva, Vasilena, Reesema, Lauren L. Siewertsz van, Tang-Tan, Angela M., Guye, Mary L. , Chang, David , Winston, Janet S., Şamli, Billur, Jansen, Rick J. , Petricoin, Emanuel F. , Goetz, Matthew P. , Tang, Amy , Guye, Mary L , Jansen, Rick J , Goetz, Matthew P , Tang, Amy H , Hoefer, Richard A., Bear, Harry D.

Mayo Clinic

Cancers | August 24, 2020 | Volume: 12 | Issue: 9 | Pages: 2392

10.3390/cancers12092392 | PMID 32846967 Get It

Triple-negative breast cancer (TNBC), characterized by the absence or low expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2), is the most aggressive subtype of breast cancer. TNBC accounts for about 15% of breast cancer cases in the U.S., and is known for high relapse rates and poor overall survival (OS). Chemo-resistant TNBC is a genetically diverse, highly heterogeneous, and rapidly evolving disease that challenges our ability to individualize treatment for incomplete responders and relapsed patients. Currently, the frontline standard chemotherapy, composed of anthracyclines, alkylating agents, and taxanes, is commonly used to treat high-risk and locally advanced TNBC. Several FDA-approved drugs that target programmed cell death protein-1 (Keytruda) and programmed death ligand-1 (Tecentriq), poly ADP-ribose polymerase (PARP), and/or antibody drug conjugates (Trodelvy) have shown promise in improving clinical outcomes for a subset of TNBC. These inhibitors that target key genetic mutations and specific molecular signaling pathways that drive malignant tumor growth have been used as single agents and/or in combination with standard chemotherapy regimens. Here, we review the current TNBC treatment options, unmet clinical needs, and actionable drug targets, including epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), androgen receptor (AR), estrogen receptor beta (ERβ), phosphoinositide-3 kinase (PI3K), mammalian target of rapamycin (mTOR), and protein kinase B (PKB or AKT) activation in TNBC. Supported by strong evidence in developmental, evolutionary, and cancer biology, we propose that the K-RAS/SIAH pathway activation is a major tumor driver, and SIAH is a new drug target, a therapy-responsive prognostic biomarker, and a major tumor vulnerability in TNBC. Since persistent K-RAS/SIAH/EGFR pathway activation endows TNBC tumor cells with chemo-resistance, aggressive dissemination, and early relapse, we hope to design an anti-SIAH-centered anti-K-RAS/EGFR targeted therapy as a novel therapeutic strategy to control and eradicate incurable TNBC in the future.
Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG
Houdt, Winan J. van , Fiore, Marco , Barretta, Francesco , Blay, Jean‐Yves , Lahat, Guy, Strauß, D. , Ahuja, Nita , Grignani, Giovanni , Quagliuolo, Vittorio , Stoeckle, Eberhard , Schrage, Yvonne , Pennacchioli, Elisabetta , Swallow, Carol J. , Canter, Robert J. , Mullen, John T. , Fairweather, Mark , Miceli, Rosalba , Raut, Chandrajit P. , Gladdy, Rebecca A. , van Houdt, Winan J , Blay, Jean-Yves , Grignani, Giovanni , Bagaria, Sanjay P , Callegaro, Dario , Fiore, Marco , Rutkowski, Piotr , González, Ricardo , Paoli, Antonino De , Cardona, Kenneth , Pillarisetty, Venu Gopal , Nessim, Carolyn , Bagaria, Sanjay P. , Callegaro, Dario , Gronchi, Alessandro

Mayo Clinic

Cancer | August 15, 2020 | Volume: 126 | Issue: 22 | Pages: 4917-4925

10.1002/cncr.33139 | PMID 32797703 Get It

Background In this series from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG), the authors examined longitudinal outcomes of patients with a second recurrence of retroperitoneal sarcoma (RPS) after complete resection of a first local recurrence (LR). Methods Data from patients undergoing resection of a first LR from January 2002 to December 2011were collected from 22 sarcoma centers. The primary outcome was overall survival (OS) after second recurrence. Results Second recurrences occurred in 400 of 567 patients (70.5%) after an R0/R1 resection of a first locally recurrent RPS. Patterns of disease recurrence were LR in 323 patients (80.75%), distant metastases (DM) in 55 patients (13.75%), and both LR and DM in 22 patients (5.5%). The main subtype among the LR group was liposarcoma (77%), whereas DM mainly were leiomyosarcomas (43.6%). In patients with a second LR only, a total of 200 patients underwent re‐resection (61.9%). The 5‐year OS rate varied significantly based on the pattern of failure ( P < .001): 45.6% for the LR group, 25.5% for the DM group, and 0% for the group with LR and DM. The only factors found to be associated with improved OS on multivariable analysis were both time between second surgery and the development of the second recurrence (32 months vs 8 months: hazard ratio, 0.44 [ P < .001]) and surgery for second recurrence (yes vs no: hazard ratio, 3.25 [ P < .001]). The 5‐year OS rate for patients undergoing surgery for a second LR was 59% versus 18% in the patients not deemed suitable for surgical resection. Conclusions Survival rates after second recurrence of RPS varied based on patterns of disease recurrence and treatment. Durable disease‐free survivors were identified after surgery for second LR in patients selected for this intervention.
Intake of Dietary Fruit, Vegetables, and Fiber and Risk of Colorectal Cancer According to Molecular Subtypes: A Pooled Analysis of 9 Studies
Hidaka, Akihisa , Harrison, Tabitha A. , Cao, Yin , Sakoda, Lori C. , Barfield, Richard , Giannakis, Marios , Phipps, Amanda I. , Figueiredo, Jane C. , Zaidi, Syed Hassan Ejaz , Berndt, Sonja I. , Borozan, Ivan , Gallinger, Steven , Gunter, Marc J. , Guinter, Mark A. , Harlid, Sophia , Moreno, Vı́ctor , Nishihara, Reiko , Obón‐Santacana, Mireia , Parfrey, Patrick S. , Slattery, Martha L. , Steinfelder, Robert S. , Wang, Xiaoliang , Woods, Michael O. , Guelpen, Bethany Van , Thibodeau, Stephen N. , Hoffmeister, Michael , Peters, Ulrike , Amitay, Efrat L , Guinter, Mark A , Harlid, Sophia , Hampel, Heather , Moreno, Victor , Ogino, Shuji , Potter, John D , Slattery, Martha L , Um, Caroline Y , Van Guelpen, Bethany , Hoffmeister, Michael , Sun, Wei , Buchanan, Daniel D , Sakoda, Lori C , Cao, Yin , Gunter, Marc J , Harrison, Tabitha A , Hidaka, Akihisa , Wang, Xiaoliang , Obón-Santacana, Mireia , Song, Mingyang , Toland, Amanda Ewart , Amitay, Efrat L. , Chan, Andrew T. , Hampel, Heather , Jenkins, Mark A. , Lin, Yi , Newcomb, Polly A. , Potter, John D. , Um, Caroline Y. , Sun, Wei , Hsu, Li , Buchanan, Daniel D. , Campbell, Peter T.

Mayo Clinic

Cancer Research | August 14, 2020 | Volume: 80 | Issue: 20 | Pages: 4578-4590

10.1158/0008-5472.can-20-0168 | PMID 32816852 Get It

Abstract Protective associations of fruits, vegetables, and fiber intake with colorectal cancer risk have been shown in many, but not all epidemiologic studies. One possible reason for study heterogeneity is that dietary factors may have distinct effects by colorectal cancer molecular subtypes. Here, we investigate the association of fruit, vegetables, and fiber intake with four well-established colorectal cancer molecular subtypes separately and in combination. Nine observational studies including 9,592 cases with molecular subtypes for microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and somatic mutations in BRAF and KRAS genes, and 7,869 controls were analyzed. Both case-only logistic regression analyses and polytomous logistic regression analyses (with one control set and multiple case groups) were used. Higher fruit intake was associated with a trend toward decreased risk of BRAF-mutated tumors [OR 4th vs. 1st quartile = 0.82 (95% confidence interval, 0.65–1.04)] but not BRAF-wildtype tumors [1.09 (0.97–1.22); P difference as shown in case-only analysis = 0.02]. This difference was observed in case–control studies and not in cohort studies. Compared with controls, higher fiber intake showed negative association with colorectal cancer risk for cases with microsatellite stable/MSI-low, CIMP-negative, BRAF-wildtype, and KRAS-wildtype tumors (Ptrend range from 0.03 to 3.4e-03), which is consistent with the traditional adenoma-colorectal cancer pathway. These negative associations were stronger compared with MSI-high, CIMP-positive, BRAF-mutated, or KRAS-mutated tumors, but the differences were not statistically significant. These inverse associations for fruit and fiber intake may explain, in part, inconsistent findings between fruit or fiber intake and colorectal cancer risk that have previously been reported. Significance: These analyses by colorectal cancer molecular subtypes potentially explain the inconsistent findings between dietary fruit or fiber intake and overall colorectal cancer risk that have previously been reported.